Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
2.

AKT3 drives adenoid cystic carcinoma development in salivary glands.

Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.

Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

3.

A20 Haploinsufficiency Aggravates Transplant Arteriosclerosis in Mouse Vascular Allografts: Implications for Clinical Transplantation.

Moll HP, Lee A, Peterson CR, Revuelta Cervantes J, Wojcik BM, Parulkar A, Mele A, LoGerfo PJ, Siracuse JJ, Csizmadia E, da Silva CG, Ferran C.

Transplantation. 2016 Nov;100(11):e106-e116.

4.

Unexpected oncosuppressive role for STAT3 in KRAS-induced lung tumorigenesis.

Grabner B, Moll HP, Casanova E.

Mol Cell Oncol. 2015 May 26;3(3):e1036199. doi: 10.1080/23723556.2015.1036199. eCollection 2016 May.

5.

Heterologous protein production using euchromatin-containing expression vectors in mammalian cells.

Zboray K, Sommeregger W, Bogner E, Gili A, Sterovsky T, Fauland K, Grabner B, Stiedl P, Moll HP, Bauer A, Kunert R, Casanova E.

Nucleic Acids Res. 2015 Sep 18;43(16):e102. doi: 10.1093/nar/gkv475. Epub 2015 May 14.

6.

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.

7.

A20 suppresses vascular inflammation by recruiting proinflammatory signaling molecules to intracellular aggresomes.

Enesa K, Moll HP, Luong L, Ferran C, Evans PC.

FASEB J. 2015 May;29(5):1869-78. doi: 10.1096/fj.14-258533. Epub 2015 Feb 9.

8.

Translational studies of A20 in atherosclerosis and cardiovascular disease.

McGillicuddy FC, Moll HP, Farouk S, Damrauer SM, Ferran C, Reilly MP.

Adv Exp Med Biol. 2014;809:83-101.

PMID:
25302367
9.

Anti-viral tetris: modulation of the innate anti-viral immune response by A20.

Arguello M, Paz S, Ferran C, Moll HP, Hiscott J.

Adv Exp Med Biol. 2014;809:49-64. Review.

PMID:
25302365
10.

A20 regulates atherogenic interferon (IFN)-γ signaling in vascular cells by modulating basal IFNβ levels.

Moll HP, Lee A, Minussi DC, da Silva CG, Csizmadia E, Bhasin M, Ferran C.

J Biol Chem. 2014 Nov 7;289(45):30912-24. doi: 10.1074/jbc.M114.591966. Epub 2014 Sep 12.

11.

A20 deficiency causes spontaneous neuroinflammation in mice.

Guedes RP, Csizmadia E, Moll HP, Ma A, Ferran C, da Silva CG.

J Neuroinflammation. 2014 Jul 16;11:122. doi: 10.1186/1742-2094-11-122.

12.

The C-terminal domain of A1/Bfl-1 regulates its anti-inflammatory function in human endothelial cells.

Guedes RP, Rocha E, Mahiou J, Moll HP, Arvelo MB, Taube JM, Peterson CR, Kaczmarek E, Longo CR, da Silva CG, Ferran C.

Biochim Biophys Acta. 2013 Jun;1833(6):1553-61. doi: 10.1016/j.bbamcr.2013.03.001. Epub 2013 Mar 13.

13.

A20-mediated modulation of inflammatory and immune responses in aortic allografts and development of transplant arteriosclerosis.

Siracuse JJ, Fisher MD, da Silva CG, Peterson CR, Csizmadia E, Moll HP, Damrauer SM, Studer P, Choi LY, Essayagh S, Kaczmarek E, Maccariello ER, Lee A, Daniel S, Ferran C.

Transplantation. 2012 Feb 27;93(4):373-82. doi: 10.1097/TP.0b013e3182419829.

14.

Contamination with recombinant IFN accounts for the unexpected stimulatory properties of commonly used IFN-blocking antibodies.

Moll HP, Freudenthaler H, Zommer A, Buchberger E, Lin XH, Crisafulli S, Pandya Y, Pestka S, Lavoie T, Brostjan C.

Eur J Immunol. 2011 Jan;41(1):252-4. doi: 10.1002/eji.200940145. Epub 2010 Nov 22. No abstract available.

15.

The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types.

Moll HP, Maier T, Zommer A, Lavoie T, Brostjan C.

Cytokine. 2011 Jan;53(1):52-9. doi: 10.1016/j.cyto.2010.09.006. Epub 2010 Oct 12.

16.

Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes.

Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C.

J Thromb Haemost. 2010 Aug;8(8):1809-19. doi: 10.1111/j.1538-7836.2010.03908.x. Epub 2010 May 12.

17.

Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells.

Moll HP, Freudenthaler H, Zommer A, Buchberger E, Brostjan C.

J Immunol. 2008 Apr 15;180(8):5250-6.

18.

Principles and performance of an electron spin echo spectrometer using far infrared lasers as excitation sources.

Moll HP, Kutter C, van Tol J, Zuckerman H, Wyder P.

J Magn Reson. 1999 Mar;137(1):46-58.

PMID:
10053132
19.

High-Frequency Electron Paramagnetic Resonance of Tm3+ Ions in Lanthanum and Thulium Ethylsulphate Single Crystals.

Moll HP, van Tol J, Wyder P, Tagirov MS, Tayurskii DA.

Phys Rev Lett. 1996 Oct 14;77(16):3459-3462. No abstract available.

PMID:
10062225
20.

Electron-spin echoes at 604 GHz using far infrared lasers.

Kutter C, Moll HP, van Tol J, Zuckermann H, Maan JC, Wyder P.

Phys Rev Lett. 1995 Apr 10;74(15):2925-2928. No abstract available.

PMID:
10058059

Supplemental Content

Support Center